Search research articles
Contact Us
Filters
Showing results (441-450 of 1,327) with videos related to
Page
of 133
Sort By:
Environmental Technology
|
April 5, 2001
The impact of residual coagulant on downstream treatment processes
E J Lees, B Noble, R Hewitt, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 3, 2002
EMG-EMG coherence in writer's cramp
Carla Cordivari, Andrew J Lees, V Peter Misra, et al.
Parkinsonism & Related Disorders
|
May 2, 2016
Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence
Robbert W K Borgemeester, Andrew J Lees, Teus van Laar
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 3, 2008
The black stuff and Konstantin Nikolaevich Tretiakoff
Andrew J Lees, Marianna Selikhova, Luiz Augusto Andrade, et al.
Advances in Neurology
|
January 1, 1987
Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology
W Poewe, A J Lees, D Steiger, et al.
Acta Neurologica Scandinavica. Supplementum
|
January 1, 1989
New approaches in the use of selegiline for the treatment of Parkinson's disease
A J Lees, J Frankel, V Eatough, et al.
JAMA Neurology
|
May 23, 2017
Concerns Regarding Opicapone as Adjunct to Levodopa Therapy-Reply
Andrew J Lees, José-Francisco Rocha, Patricio Soares-da-Silva
American Journal of Obstetrics and Gynecology
|
May 27, 2008
Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis)
J Mark Cline, Suzanne Botts, Cynthia J Lees, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research
|
January 1, 1985
Prostaglandins and pyrogen fever: another look
F Coceani, I Bishai, J Lees, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 14, 2006
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
A J Lees, V Ratziu, E Tolosa, et al.
Page
of 133
Search research articles
Search
Showing results (441-450 of 1,327) with videos related to
Sort By:
Page
of 133
Environmental Technology
|
April 5, 2001
The impact of residual coagulant on downstream treatment processes
E J Lees, B Noble, R Hewitt, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 3, 2002
EMG-EMG coherence in writer's cramp
Carla Cordivari, Andrew J Lees, V Peter Misra, et al.
Parkinsonism & Related Disorders
|
May 2, 2016
Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence
Robbert W K Borgemeester, Andrew J Lees, Teus van Laar
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 3, 2008
The black stuff and Konstantin Nikolaevich Tretiakoff
Andrew J Lees, Marianna Selikhova, Luiz Augusto Andrade, et al.
Advances in Neurology
|
January 1, 1987
Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology
W Poewe, A J Lees, D Steiger, et al.
Acta Neurologica Scandinavica. Supplementum
|
January 1, 1989
New approaches in the use of selegiline for the treatment of Parkinson's disease
A J Lees, J Frankel, V Eatough, et al.
JAMA Neurology
|
May 23, 2017
Concerns Regarding Opicapone as Adjunct to Levodopa Therapy-Reply
Andrew J Lees, José-Francisco Rocha, Patricio Soares-da-Silva
American Journal of Obstetrics and Gynecology
|
May 27, 2008
Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis)
J Mark Cline, Suzanne Botts, Cynthia J Lees, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research
|
January 1, 1985
Prostaglandins and pyrogen fever: another look
F Coceani, I Bishai, J Lees, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 14, 2006
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
A J Lees, V Ratziu, E Tolosa, et al.
Page
of 133